Next Article in Journal
Kidney Transplantation in the Diabetic Patient
Previous Article in Journal
Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients
Previous Article in Special Issue
Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author’s Institution
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(6), 1240-1268;

Alternative Donor Transplantation for Acute Myeloid Leukemia

Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 480, Minneapolis, MN 55455, USA
Hematology and Oncology Department, Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY 10305, USA
Author to whom correspondence should be addressed.
Academic Editors: Celalettin Ustun and Lucy A. Godley
Received: 14 April 2015 / Revised: 18 May 2015 / Accepted: 21 May 2015 / Published: 9 June 2015
(This article belongs to the Special Issue AML in the Molecular Age: From Biology to Clinical Management)
Full-Text   |   PDF [247 KB, uploaded 9 June 2015]


Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for adult patients with acute myeloid leukemia (AML), but its use for consolidation therapy after first remission with induction chemotherapy used to be limited to younger patients and those with suitable donors. The median age of AML diagnosis is in the late 60s. With the introduction of reduced-intensity conditioning (RIC), many older adults are now eligible to receive allo-HCT, including those who are medically less fit to receive myeloablative conditioning. Furthermore, AML patients commonly have no human leukocyte antigen (HLA)-identical or medically suitable sibling donor available to proceed with allo-HCT. Technical advances in donor matching, suppression of alloreactivity, and supportive care have made it possible to use alternative donors, such as unrelated umbilical cord blood (UCB) and partially HLA-matched related (haploidentical) donors. Outcomes after alternative donor allo-HCT are now approaching the outcomes observed for conventional allo-HCT with matched related and unrelated donors. Thus, with both UCB and haploidentical donors available, lack of donor should rarely be a limiting factor in offering an allo-HCT to adults with AML. View Full-Text
Keywords: AML; alternative donor; UCB; Haploidentical; Transplantation AML; alternative donor; UCB; Haploidentical; Transplantation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Bejanyan, N.; Haddad, H.; Brunstein, C. Alternative Donor Transplantation for Acute Myeloid Leukemia. J. Clin. Med. 2015, 4, 1240-1268.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top